The agency awarded Daiichi Sankyo’s drug breakthrough, priority review and orphan drug status during its development. Pexidartinib – which will be marketed under the Turalio trade name in the ...
AstraZeneca and Daiichi Sankyo withdrew an application in the European Union for the drug to treat a type of lung cancer in December following feedback from regulatory advisers. Mixed results from ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...
2025 The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. AstraZeneca ...
Under Dr. Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback